Cargando…

Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction

BACKGROUND: Little is known about the role of interleukin (IL) in patients with acute myocardial infarction (MI), especially soluble IL-2 receptor (sIL-2R) and IL-8. We aim to evaluate, in MI patients, the predictive value of serum sIL-2R and IL-8 for future major adverse cardiovascular events (MACE...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Kunming, Xu, Chenqi, Chen, Can, Chen, Shuqing, Zhang, Yuqian, Ding, Xiaoqiang, Xu, Xialian, Lv, Qianzhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150071/
https://www.ncbi.nlm.nih.gov/pubmed/37139133
http://dx.doi.org/10.3389/fcvm.2023.1110742
_version_ 1785035286772711424
author Pan, Kunming
Xu, Chenqi
Chen, Can
Chen, Shuqing
Zhang, Yuqian
Ding, Xiaoqiang
Xu, Xialian
Lv, Qianzhou
author_facet Pan, Kunming
Xu, Chenqi
Chen, Can
Chen, Shuqing
Zhang, Yuqian
Ding, Xiaoqiang
Xu, Xialian
Lv, Qianzhou
author_sort Pan, Kunming
collection PubMed
description BACKGROUND: Little is known about the role of interleukin (IL) in patients with acute myocardial infarction (MI), especially soluble IL-2 receptor (sIL-2R) and IL-8. We aim to evaluate, in MI patients, the predictive value of serum sIL-2R and IL-8 for future major adverse cardiovascular events (MACEs), and compare them with current biomarkers reflecting myocardial inflammation and injury. METHODS: This was a prospective, single-center cohort study. We measured serum concentrations of IL-1β, sIL-2R, IL-6, IL-8 and IL-10. Levels of current biomarkers for predicting MACEs were measured, including high-sensitivity C reactive protein, cardiac troponin T and N-terminal pro-brain natriuretic peptide. Clinical events were collected during 1-year and a median of 2.2 years (long-term) follow-up. RESULTS: Twenty-four patients (13.8%, 24/173) experienced MACEs during 1-year follow-up and 40 patients (23.1%, 40/173) during long-term follow-up. Of the five interleukins studied, only sIL-2R and IL-8 were independently associated with endpoints during 1-year or long-term follow-up. Patients with high sIL-2R or IL-8 levels (higher than the cutoff value) had a significantly higher risk of MACEs during 1-year (sIL-2R: HR 7.7, 3.3–18.0, p < 0.001; IL-8: HR 4.8, 2.1–10.7, p < 0.001) and long-term (sIL-2R: HR 7.7, 3.3–18.0, p < 0.001; IL-8: HR 4.8, 2.1–10.7, p < 0.001) follow-up. Receiver operator characteristic curve analysis regarding predictive accuracy for MACEs during 1-year follow-up showed that the area under the curve for sIL-2R, IL-8, sIL-2R combined with IL-8 was 0.66 (0.54–0.79, p = 0.011), 0.69 (0.56–0.82, p < 0.001) and 0.720 (0.59–0.85, p < 0.001), whose predictive value were superior to that of current biomarkers. The addition of sIL-2R combined with IL-8 to the existing prediction model resulted in a significant improvement in predictive power (p = 0.029), prompting a 20.8% increase in the proportion of correct classifications. CONCLUSIONS: High serum sIL-2R combined with IL-8 levels was significantly associated with MACEs during follow-up in patients with MI, suggesting that sIL-2R combined with IL-8 may be a helpful biomarker for identifying the increased risk of new cardiovascular events. IL-2 and IL-8 would be promising therapeutic targets for anti-inflammatory therapy.
format Online
Article
Text
id pubmed-10150071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101500712023-05-02 Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction Pan, Kunming Xu, Chenqi Chen, Can Chen, Shuqing Zhang, Yuqian Ding, Xiaoqiang Xu, Xialian Lv, Qianzhou Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Little is known about the role of interleukin (IL) in patients with acute myocardial infarction (MI), especially soluble IL-2 receptor (sIL-2R) and IL-8. We aim to evaluate, in MI patients, the predictive value of serum sIL-2R and IL-8 for future major adverse cardiovascular events (MACEs), and compare them with current biomarkers reflecting myocardial inflammation and injury. METHODS: This was a prospective, single-center cohort study. We measured serum concentrations of IL-1β, sIL-2R, IL-6, IL-8 and IL-10. Levels of current biomarkers for predicting MACEs were measured, including high-sensitivity C reactive protein, cardiac troponin T and N-terminal pro-brain natriuretic peptide. Clinical events were collected during 1-year and a median of 2.2 years (long-term) follow-up. RESULTS: Twenty-four patients (13.8%, 24/173) experienced MACEs during 1-year follow-up and 40 patients (23.1%, 40/173) during long-term follow-up. Of the five interleukins studied, only sIL-2R and IL-8 were independently associated with endpoints during 1-year or long-term follow-up. Patients with high sIL-2R or IL-8 levels (higher than the cutoff value) had a significantly higher risk of MACEs during 1-year (sIL-2R: HR 7.7, 3.3–18.0, p < 0.001; IL-8: HR 4.8, 2.1–10.7, p < 0.001) and long-term (sIL-2R: HR 7.7, 3.3–18.0, p < 0.001; IL-8: HR 4.8, 2.1–10.7, p < 0.001) follow-up. Receiver operator characteristic curve analysis regarding predictive accuracy for MACEs during 1-year follow-up showed that the area under the curve for sIL-2R, IL-8, sIL-2R combined with IL-8 was 0.66 (0.54–0.79, p = 0.011), 0.69 (0.56–0.82, p < 0.001) and 0.720 (0.59–0.85, p < 0.001), whose predictive value were superior to that of current biomarkers. The addition of sIL-2R combined with IL-8 to the existing prediction model resulted in a significant improvement in predictive power (p = 0.029), prompting a 20.8% increase in the proportion of correct classifications. CONCLUSIONS: High serum sIL-2R combined with IL-8 levels was significantly associated with MACEs during follow-up in patients with MI, suggesting that sIL-2R combined with IL-8 may be a helpful biomarker for identifying the increased risk of new cardiovascular events. IL-2 and IL-8 would be promising therapeutic targets for anti-inflammatory therapy. Frontiers Media S.A. 2023-04-17 /pmc/articles/PMC10150071/ /pubmed/37139133 http://dx.doi.org/10.3389/fcvm.2023.1110742 Text en © 2023 Pan, Xu, Chen, Chen, Zhang, Ding, Xu and Lv. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Pan, Kunming
Xu, Chenqi
Chen, Can
Chen, Shuqing
Zhang, Yuqian
Ding, Xiaoqiang
Xu, Xialian
Lv, Qianzhou
Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
title Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
title_full Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
title_fullStr Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
title_full_unstemmed Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
title_short Soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
title_sort soluble interleukin-2 receptor combined with interleukin-8 is a powerful predictor of future adverse cardiovascular events in patients with acute myocardial infarction
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150071/
https://www.ncbi.nlm.nih.gov/pubmed/37139133
http://dx.doi.org/10.3389/fcvm.2023.1110742
work_keys_str_mv AT pankunming solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT xuchenqi solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT chencan solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT chenshuqing solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT zhangyuqian solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT dingxiaoqiang solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT xuxialian solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction
AT lvqianzhou solubleinterleukin2receptorcombinedwithinterleukin8isapowerfulpredictoroffutureadversecardiovasculareventsinpatientswithacutemyocardialinfarction